Lots of replies and absolutely zero useful information. Obviously stocks like this don't drop to near nothing for no reason. When one tracks small biotechs we find that most of the time plunges like this are eventually followed by trial failures, so I would expect a 90% likelihood of failure in the defibrotide trials. How does the street already predict this? Look carefully at the 6/08 financial update (on the website). The USA trial completed enrollment but the DSMB raised concerns about the patients meeting enrollment criteria. What does this mean? Is this why the stock is dropping? Who knows? The company won't tell you. But I sure don't think this is the best opportunity for my money. Things are looking very shaky in Gentium land.
If you want to pay for college educations don't throw down thousands on shady fliers based on statistically irrelevant single cases. If you can't do a real due diligence you're best offf sticking with mutual funds. Now please go ahead and scream about shorting or pushing the price down or whatever baby talk is going on in your heads.
I sure wish I knew. Their new defibrotide drug for VOD saved my 5-year old daughter's life last fall. Since that time I've bought over 2,000 shares and lost over $7000 USD.
All the doctors at the Children's Hospital new for sure it was safe and had a vast chance of success. So, I am still convinced that once fully released this will be a wonderful stock to hold and I plan to pay for my girl's college with the proceeds.
$4.87 today is pretty rough to swallow but I'm just buying more.